Compare Meta Platforms Inc (META) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Recursion Pharmaceuticals Inc — how do they compare? Meta Platforms Inc trades at $718.67 (market cap $1.84T), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Meta Platforms Inc is far larger — about 859.8× Recursion Pharmaceuticals Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| META | RXRX | |
|---|---|---|
Market Cap | $1.84T | $2.14B |
Volume | 15,887,049 | 30,789,535 |
Sector | Media | Health |
52-Week High | $777.59 | $6.79 |
52-Week Low | $525.72 | $2.84 |
Typical Hold Time | 127 Days | 23 Days |
Enterprise Value | $1.86T | $1.66B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $720.89, down 0.06% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with $201B revenue in 2025 and 29.84% net income margin, though Q2 2026 earnings missed expectations. Recent AI developments including the Muse Spark launch and a $21B CoreWeave deal highlight strategic positioning in artificial intelligence infrastructure.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $781 consensus price target, representing 8% upside. Key risks include ongoing youth addiction litigation in Massachusetts and elevated capital expenditures for AI infrastructure. The stock presents growth potential through AI monetization but faces regulatory and execution challenges.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
